Can surgery boost Radiation's punch against gut and pancreatic tumors?

NCT ID NCT06016855

Recruiting now Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will receive standard surgery followed by the radioactive treatment. The goal is to see if this combination improves tumor shrinkage and delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium Lu 177 dotatate (a radioactive drug that targets tumor cells)
What this could lead to: If it works, this could show that combining surgery with targeted radiation is a more effective way to control advanced neuroendocrine tumors that have spread to the liver.
What could go wrong: This is a very small early-phase trial with only 6 participants, so results may not apply to everyone. The surgery and radiation both carry risks like infection, bleeding, or kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 liver cancer metastatic malignant neoplasm pancreatic neuroendocrine tumor pancreatic neuroendocrine tumor G1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2 METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM METASTATIC MALIGNANT NEOPLASM IN THE LIVER PANCREATIC NEUROENDOCRINE TUMOR G1 PANCREATIC NEUROENDOCRINE TUMOR G2

Contacts and locations

Locations

Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.